Clinical Study

A Randomized Phase II Study Of Perioperative Mfolfirinox Versus Gemcitabine/Nab-Paclitaxel As Therapy For Resectable Pancreatic Adenocarcinoma.

Posted Date: Apr 5, 2018

  • Investigator: John Morris
  • Specialties:
  • Type of Study: Drug

to compare the effects of two different combinations of FDA-approved chemotherapy drugs. These two combinations are called mFOLFIRINOX (oxaliplatin, irinotecan, and fluorouracil) and gemcitabine plus nab-paclitaxel. These chemotherapy drugs will be given before and after surgery. The addition of these chemotherapy drugs before surgery is a new approach that is being tested in this study. This new approach could prevent your cancer from returning, but it could also cause side-effects. This study will allow the researchers to know if it is a good idea to treat pancreatic cancer with chemotherapy drugs before surgery

Criteria:

To Be Eligible For This Study, Patients Must Have Pancreatic Cancer That Can Be Removed By Surgery.

Keywords:

Pancreatic, S1505, Resectable, Cancer, Gastrointestinal

For More Information:

Uc Cancer Institute
513-584-7698
kastla@uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.